This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Facts about Growth arrest-specific protein 2.
May be involved in the membrane ruffling procedure (By similarity). .
Human | |
---|---|
Gene Name: | GAS2 |
Uniprot: | O43903 |
Entrez: | 2620 |
Belongs to: |
---|
GAS2 family |
GAS-2; growth arrest-specific 2; growth arrest-specific protein 2; MGC32610
Mass (kDA):
34.945 kDA
Human | |
---|---|
Location: | 11p14.3 |
Sequence: | 11; NC_000011.10 (22627758..22885930) |
Ubiquitously expressed with highest levels in liver, lung, and kidney. Not found in spleen.
Cytoplasm, cytoskeleton, stress fiber. Membrane; Peripheral membrane protein. Component of the microfilament system. Colocalizes with actin fibers at the cell border and along the stress fibers in growth-arrested fibroblasts. Mainly membrane-associated. When hyperphosphorylated, accumulates at membrane ruffles.
The GAS2 marker has many uses and has been proven to be useful for researchers. This article will discuss the GAS2 markers, Vaccines, Surface localization, and Clinical applications. You will learn about the advantages and limitations of GAS2 markers. Read on to discover more. Also, find out which applications of the GAS2 marker are the best for your research.
Evidence is growing that suggests that a vaccine with GAS2 may be effective in preventing influenza. The data came from thousands of participants in placebo-controlled randomised clinical trials. This method is the gold standard in clinical trials because it minimizes bias and provides high quality scientific evidence. But how effective can a vaccine made with the GAS2 marker be? Let's take an in-depth look.
Collaboration is essential between the actors in the vaccine ecosystem to ensure flexible and fungible production of their COVID-19 vaccine. They must also be able to increase vaccine adoption. They must also consider post-pandemic as well as endemic time horizons. Last but not least, all stakeholders in the vaccine ecosystem must work together to ensure that vaccines reach the right people at the right times.
Research on vaccine delivery began after the discovery in the early 60s of messengerRNA (mRNA). However, no commercial mRNA-vaccine was available until 2020's COVID-19 outbreak. This technology is now available for COVID and has been proven safe and effective. Pfizer's COVID-19 mRNA vaccine has just received FDA approval.
The availability of COVID-19 vaccines is expected to increase in 2020. Although the initial list of approved candidates may not be large enough to cover a wide range of patients, it is likely that they will soon. These vaccines may eventually be made available to more people. COVID-19, an important vaccine for vulnerable populations, can be used in the interim. Further, it could also prove helpful for the addressing of hotspots in future waves.
The global innovation community mobilized to create a COVID-19 vaccine after COVID-19 emerged in late 2019. Within 42 days, a candidate vaccination was developed. Today, over 250 vaccine candidates have been announced globally and at least 50 are expected to enter human clinical trials by 2020. These candidates are made using a variety technologies, including viral vectors as well as protein-subunits. Some 30 of them have been tested in human studies.
COVID-19, once approved, could be available by 2021. With sufficient manufacturing capacity, this vaccine would be able to protect nearly eighty percent of the world's population. In the meantime, the potential for vaccine production is tremendous. In 2021, vaccine producers could produce five to six trillion doses of vaccines, enough to cover roughly 40 percent of the global population. It is important to remember that some vaccine candidates have yet to be tested for their effectiveness.
The development of de novo affinity reagents for surface localization with the GAS2 marker requires a significant amount of time, and there are many factors to consider in selecting candidate markers. These factors include accessibility, detectability, and suitability for large datasets. GenieScore is one metric that can be used to rank candidate cell-type-specific markers. The GenieScore calculation is based on combining consensus predictions of cell surface localization with quantitative user input data.
A study published today in the Journal of the American Medical Association described the first clinical use of the GAS2 marker. The gene encodes a protein which is widely expressed in developing mouse embryos. The gene is expressed in tissue remodeling of the genitourinary system. The results of this study support the use of this biomarker in cancer screening. Its clinical utility will need to be further investigated.
GAS2 is an oncogenic cytoplasmic gene which interacts with microtubules microfilaments microfilaments, Calponin homology Domains, and microfilaments. The gene was discovered initially in murine-fibroblasts that were under growth arrest. It also regulates cell proliferation, apoptosis, and chondrogenesis. Recent research has shown GAS2 promotes cell proliferation and suppresses Apoptosis in T cells ALL and ALBL. In addition, GAS2 inhibits hepatocarcinogenesis.
Scientists used immunohistochemistry assays to detect GAS2 expression within the ovary. This was done to further investigate its clinical value. GAS2 expression is important for the formation follicles. It can be disrupted by loss of basal-lamina development. GAS2 is also expressed in the ovaries in mice with abnormal basal linolamina. While this protein is important for follicle development, its role is still unclear.
Recent studies showed that GAS2 expression partially reversed the negative effect of miR520c-3p upon OA progression. It also prevented the induction MMP-13 or caspase-2. This marker isn't specific for OA. Therefore, further investigation is necessary. It is a promising tool for assessing OA clinically. While GAS2 overexpression has many applications, it is only currently being studied.
GAS2 expression is found in the stromal tissues of the mouse egg and has been shown to be a mediator of follicle construction and development. GAS2 expression has been observed in wild-type mice during different stages of ovarian development. Mice with a gene that is gas2 null have severely impaired fertility. Gas2 null mice develop severe defects in the ability to break down oocyte cysts. In addition, the boundaries between CL and growing follicles are disorganized.
Recent research suggests that GAS2 interacts to the Notch pathway during Ovarian development. The interaction between Gas2 and Notch signaling pathway is thought to be the main factor that promotes the growth of ovarian follicles. GAS2 also plays a vital role in female fertility. Further research is needed in order to determine whether GAS2 influences ovarian growth and reproductive health. If these findings are confirmed, GAS2 will play an important role in clinical diagnosis and therapy.
PMID: 9521882 by Collavin L., et al. cDNA characterization and chromosome mapping of the human GAS2 gene.
PMID: 24706950 by Stroud M.J., et al. GAS2-like proteins mediate communication between microtubules and actin through interactions with end-binding proteins.